10-Q: Arcus Biosciences Reports Q2 Net Income, Advances Pipeline

Arcus Biosciences achieved net income in Q2 2025, driven by a one-time revenue adjustment, while advancing key oncology programs and securing a strong cash position.

Summary

• Arcus Biosciences reported net income of $0 million for the three months ended June 30, 2025, a significant improvement from a net loss of $93 million in the same period of 2024.
• Total revenues for Q2 2025 increased by 310% to $160 million, primarily due to a $143 million cumulative catch-up in license and development services revenue following Gilead's termination of rights to the etrumadenant program.
• For the six months ended June 30, 2025, the company reported a net loss of $112 million, compared to a net loss of $97 million for the same period in 2024.
• Research and development (R&D) expenses increased by 21% to $139 million in Q2 2025 and by 17% to $261 million for the six months ended June 30, 2025, driven by increased CMC costs and early-stage development activities for casdatifan.
• As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $927 million, which is believed to be sufficient to fund planned operations for at least twelve months and through initial pivotal read-outs for domvanalimab, quemliclustat, and casdatifan.
• Initial data from the ARC-20 study evaluating casdatifan plus cabozantinib showed a 46% confirmed overall response rate in metastatic cancer patients with a manageable safety profile.
• The company initiated two new studies for casdatifan: PEAK-1 (Phase 3 in immunotherapy-experienced clear cell renal cell carcinoma) and eVOLVE-RCC02 (Phase 1b/3, AstraZeneca-sponsored, in first-line metastatic ccRCC).
• Quemliclustat, a CD73 inhibitor, received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer in July 2025.
• Gilead returned its license to the adenosine receptor antagonist program (etrumadenant) in June 2025, and its time-limited exclusive option rights to the HIF-2 program (casdatifan) expired in Q1 2025.
• Taiho Pharmaceutical opted to participate in the global Phase 3 trial of quemliclustat (PRISM-1) and made milestone payments totaling $19 million, with $12 million received in Q1 2025 and $7 million due in Q1 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the Q2 net income is largely due to a one-time accounting adjustment, the underlying operational burn is still present for the six-month period. However, the strong cash position, promising early clinical data for casdatifan leading to Phase 3, and the Orphan Drug Designation for quemliclustat are significant positive developments. Strategic prioritization of the pipeline, even if it means discontinuing some programs, is a sound long-term approach. The company appears well-funded for its near-term pivotal milestones.

Positives

• Achieved net income of $0 million in Q2 2025, a significant improvement from a $93 million net loss in Q2 2024, largely due to a $143 million revenue catch-up from Gilead's etrumadenant license termination.
• Maintained a strong liquidity position with $927 million in cash, cash equivalents, and marketable securities as of June 30, 2025, providing a runway of at least twelve months and through initial pivotal read-outs.
• Reported promising initial data from the ARC-20 study for casdatifan plus cabozantinib, showing a 46% confirmed overall response rate in metastatic cancer patients with a manageable safety profile.
• Initiated two new clinical studies for casdatifan (PEAK-1 Phase 3 and eVOLVE-RCC02 Phase 1b/3), indicating advancement of a key pipeline asset.
• Quemliclustat received Orphan Drug Designation from the FDA for pancreatic cancer, which can provide market exclusivity and other development incentives.
• Gilead's option rights to the HIF-2 program (casdatifan) expired, allowing Arcus to retain full rights to this promising asset.
• Secured additional funding through a $150 million underwritten offering in Q1 2025 and a $50 million draw from the Hercules term loan in Q2 2025, bolstering financial flexibility.

Negatives

• Despite the Q2 2025 net income, the company reported an increased net loss for the six months ended June 30, 2025, at $112 million compared to $97 million in the prior year, indicating continued operational burn.
• The significant Q2 2025 revenue increase was primarily a one-time accounting adjustment ($143 million cumulative catch-up) rather than recurring product sales, masking underlying operational losses.
• Gilead returned its license to the etrumadenant program, indicating a setback or deprioritization for that specific investigational product.
• The company has a history of operating losses and has never generated revenue from product sales, anticipating continued significant losses for the foreseeable future.
• Long-term debt increased to $97 million as of June 30, 2025, from $48 million at December 31, 2024, due to additional draws from the Hercules loan facility.
• The company elected the maximum payment-in-kind deferral for interest on the Hercules loan effective July 1, 2025, which adds to the principal balance.

Risks

• History of operating losses and no revenue from product sales, with anticipated significant losses for the foreseeable future.
• Need to obtain additional funding; inability to raise capital could force restriction or elimination of product development programs.
• Inability to obtain regulatory approval for investigational products or significant delays in doing so.
• Preliminary, topline, and interim clinical data are subject to audit and verification, potentially resulting in material changes.
• Enrollment and retention of subjects in clinical trials is expensive, time-consuming, and can be hindered by competing treatments, geopolitical instability, and public health epidemics.
• Serious adverse events, undesirable side effects, or unexpected properties of investigational products may lead to discontinuation, refusal of approval, or limitations on use.
• Failure in developing intra-portfolio combinations to achieve superior outcomes could impair strategic objectives.
• Certain investigational products may require companion diagnostics; failure to develop, validate, and obtain regulatory approval for such tests could harm product development.
• Dependence on the collaboration with Gilead Sciences, Inc. for research, development, manufacture, and commercialization, with risks if the collaboration is unsuccessful.
• Reliance on third parties to conduct clinical trials and perform research/preclinical studies; failure to perform could delay programs or increase costs.
• Even with marketing approval, commercialization may not be successful.
• Commercial success is dependent on obtaining coverage and reimbursement from government or third-party payors, which may be delayed or insufficient.
• Obtaining regulatory approval in one jurisdiction does not guarantee approval in others.
• Investigational products intended as biologic products may face biosimilar competition sooner than anticipated.
• Breach of obligations under in-license agreements could lead to damages or loss of rights to investigational products.
• Inability to obtain and maintain sufficient intellectual property protection or if the scope is not broad enough, competitors could develop similar products.
• Potential involvement in lawsuits alleging infringement of third-party intellectual property rights or to protect/enforce patents.
• Changes in patent law could diminish the value of patents.
• Reliance on trade secrets and proprietary know-how, which can be difficult to protect and enforce.
• Difficulties in managing business expansion and growth.
• Substantial competition from other companies developing products in the same class.
• Internal information technology systems and those of third parties are subject to failure, security breaches, and other disruptions.
• Failure to comply with privacy and data protection laws, regulations, or other obligations could lead to government enforcement actions, private litigation, and/or adverse publicity.
• Changes in healthcare law and implementing regulations, as well as healthcare policy, may impact the business.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Unfavorable global economic, political, and trade conditions could adversely affect the business, including reliance on Chinese manufacturers like WuXi Biologics.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Changes in tax laws and regulations or exposure to additional tax liabilities.
• Stock price volatility, potentially declining regardless of operating performance.
• Quarterly operating results may fluctuate significantly or fall below expectations.
• Concentration of stock ownership (Gilead) may limit other stockholders' ability to influence corporate matters.
• Delaware law and provisions in the company's charter/bylaws could make a merger, tender offer, or proxy contest difficult.
• Exclusive forum provisions for disputes could limit stockholders' ability to obtain a favorable judicial forum.
• Sales of substantial amounts of shares may cause the stock price to decline.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate and timely financial statements.

Future Outlook

The company expects R&D expenses to peak in 2025 and then decline meaningfully over the next few years as programs advance towards regulatory approval, while also anticipating the advancement of new programs into the clinic. General and administrative expenses are expected to remain stable for the remainder of 2025. Current cash, cash equivalents, and marketable securities are believed to be sufficient to fund planned operations for at least twelve months from the filing date and through initial pivotal read-outs for domvanalimab, quemliclustat, and casdatifan, including the PEAK-1 study.

Management Comments

• We are a clinical-stage biopharmaceutical company focused on creating best-in-class therapies.
• Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies targeting lung and GI cancers.
• Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.
• Our vision is to create, develop and commercialize highly differentiated therapies that have a meaningful impact on patients.
• We expect our R&D expenses to peak in 2025 and then decline meaningfully during the next few years as we advance our programs towards regulatory approval.
• We also expect to advance new programs into the clinic.
• We anticipate that our G&A expenses will be stable for the remainder of this year.
• Based on our existing business plan, we believe that our cash, cash equivalents, marketable securities and existing facilities as of June 30, 2025 will be sufficient to fund our planned level of operations for a period of at least twelve months following the date of filing of this report and provide funding through our initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan, which include PEAK-1.
• This is based on disciplined prioritization of our resources to these programs. For example, we have paused further development for etrumadenant in third-line metastatic colorectal cancer to focus our resources on our late stage clinical portfolio and research programs.

Industry Context

Arcus Biosciences operates in the highly competitive and rapidly evolving immuno-oncology and cancer treatment segments of the biopharmaceutical industry. As a clinical-stage company, its financial performance is heavily reliant on successful drug development, strategic collaborations, and capital raises, rather than product sales. The company's focus on intra-portfolio combinations aligns with a broader industry trend of developing synergistic multi-agent therapies to improve patient outcomes. The discontinuation of the etrumadenant program and the return of its license by Gilead, while a specific program setback, reflects a common strategic prioritization in drug development to reallocate resources to more promising or advanced assets, such as the casdatifan program which is now entering Phase 3 trials. The receipt of Orphan Drug Designation for quemliclustat highlights the industry's pursuit of therapies for rare diseases, which often come with regulatory incentives.

Comparison to Industry Standards

• Arcus Biosciences' reported 46% confirmed overall response rate for casdatifan plus cabozantinib in metastatic cancer patients (ARC-20 study) is a strong early-stage clinical signal, particularly for a Phase 1b trial. While direct comparisons are difficult without full trial details, such response rates in early-stage oncology trials can be highly competitive and de-risk further development.
• The initiation of Phase 3 studies (PEAK-1 for casdatifan, PRISM-1 for quemliclustat, and ongoing STAR-121/STAR-221 for domvanalimab/zimberelimab) positions Arcus in the late-stage development phase, a critical and capital-intensive period for biopharmaceutical companies. This is comparable to peers like Mirati Therapeutics (now BMS) with KRAZATI or Seagen (now Pfizer) with ADCETRIS, which have advanced through similar late-stage pipelines.
• The company's reliance on a major pharmaceutical partner like Gilead for co-development and commercialization (e.g., for domvanalimab, zimberelimab, quemliclustat) is a common strategy for smaller biotechs to mitigate financial risk and leverage larger partners' global reach and resources, similar to collaborations seen between smaller biotechs and large pharma such as Merck, Roche, or Bristol Myers Squibb.
• The decision to pause etrumadenant development and Gilead's return of its license is a strategic portfolio management decision, common in the industry where companies frequently re-evaluate pipeline assets based on emerging data, competitive landscape, and resource allocation. This is a standard practice to optimize R&D spend, similar to how larger companies like Pfizer or Novartis periodically prune their pipelines.
• The company's cash runway of at least 12 months, extending through pivotal read-outs, is a healthy position for a clinical-stage biotech, providing stability for ongoing trials. This is generally considered a positive indicator of financial health compared to companies with shorter cash runways that face more immediate financing pressures.

Corporate Governance

Related Party Transactions

• Gilead Sciences, Inc. is a significant related party, holding approximately 29.5% of outstanding common stock as of June 30, 2025, and having the right to designate three board members.
• Under the Gilead Collaboration Agreement, Arcus recognized $160 million and $188 million in revenue for the three and six months ended June 30, 2025, respectively, with a significant portion from license and development services.
• A cumulative catch-up to revenue of $143 million was recognized in Q2 2025 due to Gilead's termination of rights to the etrumadenant program.
• Arcus recognized net expense to Gilead of $13 million and $8 million for the three and six months ended June 30, 2025, respectively, allocated between R&D and G&A.
• As of June 30, 2025, Arcus had a net $13 million payable to Gilead in Accounts payable.
• Receivable from collaboration partners included $4 million from Gilead at June 30, 2025, and $6 million at December 31, 2024.
• Deferred revenue included $71 million (current) and $60 million (noncurrent) related to Gilead at June 30, 2025.
• Gilead purchased 1.4 million shares of Arcus common stock for $15 million in the Q1 2025 underwritten offering.
• Taiho Pharmaceutical Co., Ltd is a collaboration partner, with Arcus recognizing net reimbursements from Taiho of $8 million and $17 million for the three and six months ended June 30, 2025, respectively, as a reduction in R&D expense.
• Taiho became obligated to make milestone payments totaling $19 million for PRISM-1, with $12 million received in Q1 2025 and $7 million due in Q1 2026.

Stakeholder Impact

• Shareholders: Potential for increased value from successful clinical trial outcomes and pipeline advancements, but also risk of dilution from future capital raises and stock price volatility. Gilead's significant ownership (29.5%) and board representation could influence corporate decisions.
• Employees: Continued growth in business operations and R&D capabilities, but also potential for resource reallocation impacting specific programs (e.g., etrumadenant).
• Patients: Development of new, highly differentiated therapies for various cancers (lung, GI, pancreatic, renal cell carcinoma) offers potential new treatment options.
• Collaboration Partners (Gilead, Taiho, AstraZeneca): Continued strategic partnerships are crucial for funding, development, and commercialization, with ongoing adjustments to agreements and shared responsibilities.
• Creditors (Hercules Capital): Increased debt obligations and the election of payment-in-kind interest deferral indicate reliance on debt financing, which impacts future cash flows for repayment.

Next Steps

• Advance casdatifan into Phase 3 studies (PEAK-1 and eVOLVE-RCC02).
• Continue development of domvanalimab, zimberelimab, and quemliclustat in ongoing Phase 3 registrational studies.
• Manage R&D expenses, expecting them to peak in 2025 and then decline meaningfully as programs advance towards regulatory approval.
• Advance new programs into the clinic.
• Monitor and manage the Hercules Capital loan, including the elected payment-in-kind deferral for interest.
• Assess the potential impact of new accounting standards (ASU 2024-03 and ASU 2023-09) on future financial disclosures.

Key Dates

Recommendation

Arcus Biosciences presents a mixed financial picture, with a Q2 net income driven by a one-time accounting adjustment, but continued operational losses for the six-month period. However, the company maintains a strong cash position, providing a runway through key pivotal clinical trial read-outs. The promising early clinical data for casdatifan and its advancement to Phase 3, coupled with the Orphan Drug Designation for quemliclustat, represent significant positive pipeline developments. The strategic decision to deprioritize etrumadenant, while a setback for that specific program, reflects a disciplined approach to resource allocation. Given the inherent risks of clinical-stage biopharma, including reliance on collaborations and the need for future funding, the stock is a 'hold' for investors who are comfortable with the risk profile and believe in the long-term potential of the pipeline, particularly casdatifan and domvanalimab, but it is not a 'buy' due to the continued operational losses and the one-time nature of the Q2 revenue boost, nor a 'sell' given the strong cash position and clinical progress.

Keywords

Biopharmaceutical, Oncology, Clinical-stage, Immuno-oncology, TIGIT, PD-1, HIF-2, CD73, Adenosine Receptor Antagonist, Cancer therapy, Drug development, Clinical trials, Partnerships, Gilead, Taiho, AstraZeneca, Orphan Drug Designation, Metastatic cancer, Renal cell carcinoma, Pancreatic cancer, Biologics, SEC filing, 10-Q